drugset / Trial / NCT00331500
Olopatadine 0.2% for the Treatment of Allergic Conjunctivitis
RandomizedParallel-groupTriple-blindTreatment
Summary
The purpose of this study is to demonstrate that Olopatadine 0.2% is superior to vehicle in the treatment of the signs and symptoms associated with allergic conjunctivitis or rhinoconjunctivitis.
Timeline
- Start
- 2006-04-18
- Primary completion
- 2006-07-27
- Completion
- 2006-07-27
Publications
- Results https://www.ncbi.nlm.nih.gov/pubmed/23379201
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Olopatadine | Other / unclassified | 0.2 % | Other |